Bullish
Eli Lilly's stock rises 3.56% after FDA approves Onswik insulin and InnoCare deal
Eli Lilly's stock surged 3.56% following the FDA's approval of Onswik, a once-weekly basal insulin for type 2 diabetes, and the announcement of a research and license agreement with InnoCare Pharma valued over $3 billion. These developments are expected to enhance Lilly's position in the diabetes treatment market and expand its oncology pipeline.
Key points
- FDA approves Onswik, a once-weekly basal insulin for type 2 diabetes.
- Eli Lilly announces a $3 billion agreement with InnoCare Pharma.
- Stock price increases by 3.56% following the announcements.
Sources
AI-generated from public news sources. Not financial advice.
